Lung Cancer Trials
Select Clinical Trial
Protocol Number: ALCHEMIST
Protocol Title: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial
Eligibility: Men or women, ages 18 or older, diagnosed with Stage IIIA, II or large IB non-small cell lung cancer (NSCLC).
Contact Information: (910) 715-2200
____________________________________________________________________________________________
Protocol Number: MS200647_0005
Protocol Title: A multicenter, double blind, randomized, controlled study of M7824 with concurrent chemoradiation followed by M7824 versus concurrent chemoradiation plus placebo followed by Durvalumab
Eligibility: Men or women, ages 18 and older, diagnosed with non-small cell lung cancer, stage III locally advanced, unresectable disease.
Contact Information: (910) 715-2200
____________________________________________________________________________________________
Protocol Number: LUNGMAP
Protocol Title: Master Protocol to evaluate biomarker-driven therapies and immunotherapies in previously-treated non-small cell lung cancer (Lung-MAP Screening Study)
Eligibility: Men or women, ages 18 and older, diagnosed with non-small cell lung cancer, DISEASE MUST BE EITHER ADVANCED, stage IIIB or IV or recurrent.
Contact Information: (910) 715-2200
____________________________________________________________________________________________
Protocol Number: NRG-LU005
Protocol Title: LIMITED STAGE SMALL CELL LUNG CANCER (LS-SCLC): A PHASE II/III RANDOMIZED STUDY OF CHEMORADIATION VERSUS CHEMORADIATION PLUS ATEZOLIZUMAB
Eligibility: Men or women, ages 18 and older, diagnosed with limited stage small cell lung cancer.
Contact Information: (910) 715-2200
____________________________________________________________________________________________
Protocol Number: FDI 209
Protocol Title: A Prospective Longitudinal Collection of Peripheral Blood to Support the Validation of Biomarkers as an Aid in Monitoring Disease in Patients with all Stages of Lung Cancer
Eligibility: Men and women age 18 and older, diagnosed with Lung Cancer.
Contact Information: (910) 715-2200
____________________________________________________________________________________________
Protocol Number: SWOG 1914; NCT04214262
Protocol Title: A Randomized Phase III Trial of Induction/ Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage Non-Small Cell Lung Cancer
Eligibility: Men and women age 18 and older, diagnosed with Early Stage Non-Small Cell Lung Cancer that are not candidates for surgical resection.
Contact Information: (910) 715-2200
____________________________________________________________________________________________
Protocol Number: SWOG 1929; NCT04334941
Protocol Title: Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab in Combination with Talazoparib in Patients with SLFN11 Positive Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Eligibility: Men and women age 18 and older, diagnosed with Extensive Stage Small Cell lung cancer.
Contact Information: (910) 715-2200